Microbiological and pharmacological data useful for the treatment of Lyme disease. Treatment and follow up of early Lyme disease (erythema migrans);Bases microbiologiques et pharmacologiques du traitement de la borréliose de Lyme. Traitement et suivi de la phase aiguë (érythème migrant)

Medecine et Maladies Infectieuses

Volumn 37, Issue 7-8, 2007, Pages 394-409

  Martinot, M ^a  

^a Pasteur Hospital   (France)

Author keywords

Erythema migrans; Lyme disease

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AZITHROMYCIN; AZTREONAM; BETA LACTAM ANTIBIOTIC; CEFACLOR; CEFIXIME; CEFOTAXIME; CEFTRIAXONE; CEFUROXIME AXETIL; CLARITHROMYCIN; DALFOPRISTIN; DOXYCYCLINE; ERYTHROMYCIN; IMIPENEM; MACROLIDE; MEROPENEM; MEZLOCILLIN; MINOCYCLINE; OXACILLIN; PENICILLIN G; PENICILLIN V; PIPERACILLIN; PROBENECID; ROXITHROMYCIN; TEICOPLANIN; TELITHROMYCIN; TETRACYCLINE; UNINDEXED DRUG; VANCOMYCIN; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBODY PRODUCTION; ARTICLE; BORRELIA BURGDORFERI; CLINICAL TRIAL; COLITIS; CONTROLLED CLINICAL TRIAL; ERYTHEMA CHRONICUM MIGRANS; FOLLOW UP; HUMAN; HYPOTENSION; LYME DISEASE; MINIMUM INHIBITORY CONCENTRATION; PROGNOSIS; RECOMMENDED DRUG DOSE; ANIMAL; CLASSIFICATION; DISEASE MODEL; DRUG ADMINISTRATION; DRUG EFFECT; IMMUNE DEFICIENCY; IMMUNOLOGY; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; PATHOPHYSIOLOGY; REVIEW;

ANIMALS; ANTI-BACTERIAL AGENTS; BORRELIA BURGDORFERI GROUP; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; HUMANS; IMMUNOLOGIC DEFICIENCY SYNDROMES; LYME DISEASE; MICROBIAL SENSITIVITY TESTS;

EID: 34548457599     PISSN: 0399077X     EISSN: 17696690     Source Type: Journal    
DOI: 10.1016/j.medmal.2006.01.028     Document Type: Article

References (101)

1. Hunfeld K.P., Kraiczy P., Kekoukh E., Schafer V., and Brade V. Standardised in vitro susceptibility testing of Borrelia burgdorferi against well-known and newly developed antimicrobial agents: possible implications for new therapeutic approaches to Lyme disease. Int. J. Med. Microbiol. 291 Suppl 33 (2002) 125-137
2. Hunfeld K.P., Weigand J., Wichelhaus T.A., Kekoukh E., Kraiczy P., and Brade V. In vitro activity of mezlocillin, meropenem, aztreonam, vancomycin, teicoplanin, ribostamycin and fusidic acid against Borrelia burgdorferi. Int. J. Antimicrob. Agents 17 3 (2001) 203-208
3. Hunfeld K.P., Wichelhaus T.A., Kekoukh E., Molitor M., Kraiczy P., and Brade V. In vitro susceptibility of the Borrelia burgdorferi sensu lato complex to ABT-773, a novel ketolide. J. Antimicrob. Chemother. 48 3 (2001) 447-449
4. Terekhova D., Sartakova M.L., Wormser G.P., Schwartz I., and Cabello F.C. Erythromycin resistance in Borrelia burgdorferi. Antimicrob. Agents Chemother. 46 11 (2002) 3637-3640
5. Baradaran-Dilmaghani R., and Stanek G. In vitro susceptibility of thirty Borrelia strains from various sources against eight antimicrobial chemotherapeutics. Infection 24 1 (1996) 60-63
6. Janovska D., Hulinska D., and Godova T. Sensitivity of Borrelia burgdorferi strains isolated in the Czech Republic. Cent. Eur. J. Public Health 9 1 (2001) 38-40
7. Levin J.M., Nelson J.A., Segreti J., Harrison B., Benson C.A., and Strle F. In vitro susceptibility of Borrelia burgdorferi to 11 antimicrobial agents. Antimicrob. Agents Chemother. 37 7 (1993) 1444-1446
8. Hunfeld K.P., Kraiczy P., Wichelhaus T.A., Schafer V., and Brade V. Colorimetric in vitro susceptibility testing of penicillins, cephalosporins, macrolides, streptogramins, tetracyclines, and aminoglycosides against Borrelia burgdorferi isolates. Int. J. Antimicrob. Agents 15 1 (2000) 11-17
9. Hunfeld K.P., Kraiczy P., Wichelhaus T.A., Schafer V., and Brade V. New colorimetric microdilution method for in vitro susceptibility testing of Borrelia burgdorferi against antimicrobial substances. Eur. J. Clin. Microbiol. Infect. Dis. 19 1 (2000) 27-32
10. Dever L.L., Jorgensen J.H., and Barbour A.G. In vitro antimicrobial susceptibility testing of Borrelia burgdorferi: a microdilution MIC method and time-kill studies. J. Clin. Microbiol. 30 10 (1992) 2692-2697
11. Sambri V., Massaria F., Cevenini R., and La Placa M. In-vitro susceptibility of Borrelia burgdorferi and Borrelia hermsii to ten antimicrobial agents. J. Chemother. 2 6 (1990) 348-350
12. Johnson S.E., Klein G.C., Schmid G.P., and Feeley J.C. Susceptibility of the Lyme disease spirochete to seven antimicrobial agents. Yale J. Biol. Med. 57 4 (1984) 549-553
13. Johnson R.C., Kodner C., and Russell M. In vitro and in vivo susceptibility of the Lyme disease spirochete, Borrelia burgdorferi, to four antimicrobial agents. Antimicrob. Agents Chemother. 31 2 (1987) 164-167
14. Johnson R.C., Kodner C., Russell M., and Girard D. In vitro and in vivo susceptibility of Borrelia burgdorferi to azithromycin. J. Antimicrob. Chemother. 25 Suppl A (1990) 33-38
15. Johnson R.C., Kodner C.B., Jurkovich P.J., and Collins J.J. Comparative in vitro and in vivo susceptibilities of the Lyme disease spirochete Borrelia burgdorferi to cefuroxime and other antimicrobial agents. Antimicrob. Agents Chemother. 34 11 (1990) 2133-2136
16. Mursic V.P., Wilske B., Schierz G., Holmburger M., and Suss E. In vitro and in vivo susceptibility of Borrelia burgdorferi. Eur. J. Clin. Microbiol. 6 4 (1987) 424-426
17. Preac-Mursic V., Wilske B., and Schierz G. European Borrelia burgdorferi isolated from humans and ticks culture conditions and antibiotic susceptibility. Zbl Bakt Hyg A 263 (1986) 112-118
18. Wretlind B., Johnson R.C., Hansen K., and Preac-Mursic V. Antibiotic susceptibility of Borrelia burgdorferi in vitro and in animal models. Scand. J. Infect. Dis. Suppl. 77 (1991) 143-144
19. Sicklinger M., Wienecke R., and Neubert U. In vitro susceptibility testing of four antibiotics against Borrelia burgdorferi: a comparison of results for the three genospecies Borrelia afzelii, Borrelia garinii, and Borrelia burgdorferi sensu stricto. J. Clin. Microbiol. 41 4 (2003) 1791-1793
20. Ruzic-Sabljic E., Podreka T., Maraspin V., and Strle F. Susceptibility of Borrelia afzelii strains to antimicrobial agents. Int. J. Antimicrob. Agents 25 6 (2005) 474-478
21. Hunfeld K.P., Ruzic-Sabljic E., Norris D.E., Kraiczy P., and Strle F. In vitro susceptibility testing of Borrelia burgdorferi sensu lato isolates cultured from patients with erythema migrans before and after antimicrobial chemotherapy. Antimicrob. Agents Chemother. 49 4 (2005) 1294-1301
22. Hansen K., Hovmark A., Lebech A.M., Lebech K., Olsson I., Halkier-Sorensen L., et al. Roxithromycin in Lyme borreliosis: discrepant results of an in vitro and in vivo animal susceptibility study and a clinical trial in patients with erythema migrans. Acta Derm. Venereol. 72 4 (1992) 297-300
23. Agger W., Callister S., and Jobe D. In vitro susceptibilities of Borrelia burgdorferi to five oral cephalosporins and ceftriaxone. Antimicrob. Agents Chemother. 36 8 (1992) 1788-1790
24. Gasser R., Wendelin I., Resinger E., Bergloff J., FeIgl B., Schafahalter I., et al. Roxithromycin in the treatment of Lyme disease: update and perspectives. Infection 23 Suppl 1 (1995) S39-S43
25. Hunfeld K.P., Ruzic-Sabljic E., Norris D.E., Kraiczy P., and Strle F. Risk of culture-confirmed borrelial persistence in patients treated for erythema migrans and possible mechanisms of resistance. Int. J. Med. Microbiol. 22 296S1 (2006) 233-241
26. Jackson Charlene F.J., Boylan J., and Gherardini F. Evidence of a conjugal erythromycin resistance element in the Lyme disease spirochete Borrelia burgdorferi. Intern. J. Antimicrobial Agents 27 5 (2006) 367-377
27. Brorson O., and Brorson S.H. An in vitro study of the susceptibility of mobile and cystic forms of Borrelia burgdorferi to metronidazole. APMIS 107 6 (1999) 566-576
28. Brorson O., and Brorson S.H. Susceptibility of motile and cystic forms of Borrelia burgdorferi to ranitidine bismuth citrate. Int. Microbiol. 4 4 (2001) 209-215
29. Brorson O., and Brorson S.H. An in vitro study of the susceptibility of mobile and cystic forms of Borrelia burgdorferi to hydroxychloroquine. Int. Microbiol. 5 1 (2002) 25-31
30. Brorson O., and Brorson S.H. An in vitro study of the susceptibility of mobile and cystic forms of Borrelia burgdorferi to tinidazole. Int. Microbiol. 7 2 (2004) 139-142
31. Pavia C., Inchiosa Jr. M.A., and Wormser G.P. Efficacy of short-course ceftriaxone therapy for Borrelia burgdorferi infection in C3H mice. Antimicrob. Agents Chemother. 46 1 (2002) 132-134
32. Kazragis R.J., Dever L.L., Jorgensen J.H., and Barbour A.G. In vivo activities of ceftriaxone and vancomycin against Borrelia spp. in the mouse brain and other sites. Antimicrob. Agents Chemother. 40 11 (1996) 2632-2636
33. Moody K.D., Adams R.L., and Barthold S.W. Effectiveness of antimicrobial treatment against Borrelia burgdorferi infection in mice. Antimicrob. Agents Chemother. 38 7 (1994) 1567-1572
34. Konishi T., and Nakao M. Antibiotic treatment in mice infected with Japanese Borrelia garinii: efficacy of ceftriaxone for eradicating the infection induced by Ixodes persulcatus tick bites. Microbiol. Immunol. 41 2 (1997) 165-168
35. Gaudy C.B.J. Antibiotiques : pharmacologie et thérapeutique: Elsevier (2005)
36. Goodman L.F., Gilman A., Brunton L., Lazo S., and Parker K.L. The Pharmacological basis of therapeutics (2006), Mc Graw Hill, New York
37. André B. Antibiotiques Agents Antibactériens et Antifongiques: ellipses (1999)
38. Strausbaugh L.J., Girgis N.I., Mikhail I.A., Edman D.C., Miner W.F., and Yassin M.W. Penetration of amoxicilline into cerebrospinal fluid. Antimicrob. Agents Chemother. 14 6 (1978) 899-902
39. Vree T.B., and Hekster Y.A. Pharmacokinetics and tissue concentrations of cefuroxime. Pharm. Weekbl. Sci. 12 6A (1990) 262-266 (discussion 7)
40. Philippon A, Arlet G, Schlemmer. B. Bêtalactamines (II). In EMC:1994. p. 1-28.
41. E B-B. Tissue distribution of macrolide antibiotics. In: Blackwell A. (Ed). Macrolides, chemistry, pharmacology and clinical uses (1993)
42. Jaruratanasirikul S., Hortiwakul R., Tantisarasart T., Phuenpathom N., and Tussanasunthornwong S. Distribution of azithromycin into brain tissue, cerebrospinal fluid, and aqueous humor of the eye. Antimicrob. Agents Chemother. 40 3 (1996) 825-826
43. Karlsson M., Hammers S., Nilsson-Ehle I., Malmborg A.S., and Wretlind B. Concentrations of doxycycline and penicillin G in sera and cerebrospinal fluid of patients treated for neuroborreliosis. Antimicrob. Agents Chemother. 40 5 (1996) 1104-1107
44. Dotevall L., and Hagberg L. Penetration of doxycycline into cerebrospinal fluid in patients treated for suspected Lyme neuroborreliosis. Antimicrob. Agents Chemother. 33 7 (1989) 1078-1080
45. Dotevall L., Alestig K., Hanner P., Norkrans G., and Hagberg L. The use of doxycycline in nervous system Borrelia burgdorferi infection. Scand. J. Infect. Dis. Suppl. 53 (1988) 74-79
46. Pfister H.W., Preac-Mursic V., Wilske B., and Einhaupl K.M. Cefotaxime vs penicillin G for acute neurologic manifestations in Lyme borreliosis. A prospective randomized study. Arch. Neurol. 46 11 (1989) 1190-1194
47. Pfister H.W., Preac-Mursic V., Wilske B., Schielke E., Sorgel F., and Einhaupl K.M. Randomized comparison of ceftriaxone and cefotaxime in Lyme neuroborreliosis. J. Infect. Dis. 163 2 (1991) 311-318
48. Luft B., Volkman D., Halperin J., and Dattwyler R. New chemotherapeutic approaches in the treatment of Lyme borreliosis. Ann. N Y Acad. Sci. 539 (1988) 352-361
49. Preac Mursic V., Marget W., Busch U., Pleterski Rigler D., and Hagl. Kill kinetics of Borrelia burgdorferi and bacterial findings in relation to the treatment of Lyme Borreliosis. Infection 24 1 (1996) 9-18
50. Zeidner N., Brandt K., Dadey E., Dolan M., Happ C., and Piesman J. Sustained-release formulation of doxycycline hyclate for prophylaxis of tick bite infection in a murine model of Lyme borreliosis. Antimicrob. Agents Chemother. 48 7 (2004) 2697-2699
51. Steere A.C., Malawista S.E., Newman J.H., Spieler P.N., and Bartenhagen N.H. Antibiotic therapy in Lyme disease. Ann. Intern. Med. 93 1 (1980) 1-8
52. Weber K., Preac-Mursic V., Wilske B., Thurmayr R., Neubert U., and Scherwitz C. A randomized trial of ceftriaxone versus oral penicillin for the treatment of early European Lyme borreliosis. Infection 18 2 (1990) 91-96
53. Steere A.C., Hutchinson G.J., Rahn D.W., Sigal L.H., Craft J.E., DeSanna E.T., et al. Treatment of the early manifestations of Lyme disease. Ann. Intern. Med. 99 1 (1983) 22-26
54. Dattwyler R.J., Volkman D.J., Conaty S.M., Platkin S.P., and Luft B.J. Amoxycillin plus probenecid versus doxycycline for treatment of erythema migrans borreliosis. Lancet 336 8728 (1990) 1404-1406
55. Breier F., Kunz G., Klade H., Stanek G., and Aberer E. Erythema migrans: three weeks treatment for prevention of late Lyme borreliosis. Infection 24 1 (1996) 69-72
56. Dattwyler R.J., Luft B.J., Kunkel M.J., Finkel M.F., Wormser G.P., Rush T.J., et al. Ceftriaxone compared with doxycycline for the treatment of acute disseminated Lyme disease. N. Engl. J. Med. 337 5 (1997) 289-294
57. Nadelman R.B., Luger S.W., Frank E., Wisniewski M., Collins J.J., and Wormser G.P. Comparison of cefuroxime axetil and doxycycline in the treatment of early Lyme disease. Ann. Intern. Med. 117 4 (1992) 273-280
58. Luger S.W., Paparone P., Wormser G.P., Nadelman R.B., Grunwaldt E., Gomez G., et al. Comparison of cefuroxime axetil and doxycycline in treatment of patients with early Lyme disease associated with erythema migrans. Antimicrob. Agents Chemother. 39 3 (1995) 661-667
59. Massarotti E.M., Luger S.W., Rahn D.W., Messner R.P., Wong J.B., Johnson R.C., et al. Treatment of early Lyme disease. Am. J. Med. 92 4 (1992) 396-403
60. Strle F., Ruzic E., and Cimperman J. Erythema migrans: comparison of treatment with azithromycin, doxycycline and phenoxymethylpenicillin. J. Antimicrob. Chemother. 30 4 (1992) 543-550
61. Weber K., Wilske B., Preac-Mursic V., and Thurmayr R. Azithromycin versus penicillin V for the treatment of early Lyme borreliosis. Infection 21 6 (1993) 367-372
62. Luft B.J., Dattwyler R.J., Johnson R.C., Luger S.W., Bosler E.M., Rahn D.W., et al. Azithromycin compared with amoxicillin in the treatment of erythema migrans. A double blind, randomized, controlled trial. Ann. Intern. Med. 124 9 (1996) 785-791
63. Strle F., Preac-Mursic V., Cimperman J., Ruzic E., Maraspin V., and Jereb M. Azithromycin versus doxycycline for treatment of erythema migrans: clinical and microbiological findings. Infection 21 2 (1993) 83-88
64. Barsic B., Maretic T., Majerus L., and Strugar J. Comparison of azithromycin and doxycycline in the treatment of erythema migrans. Infection 28 3 (2000) 153-156
65. Dattwyler R.J., Grunwaldt E., and Luft B.J. Clarithromycin in treatment of early Lyme disease: a pilot study. Antimicrob. Agents Chemother. 40 2 (1996) 468-469
66. Steere A.C. Lyme disease. N. Engl. J. Med. 345 2 (2001) 115-125
67. Arnez M., Radsel-Medvescek A., Pleterski-Rigler D., Ruzic-Sabljic E., and Strle F. Comparison of cefuroxime axetil and phenoxymethyl penicillin for the treatment of children with solitary erythema migrans. Wien Klin Wochenschr. 111 22-23 (1999) 916-922
68. Eppes S.C., and Childs J.A. Comparative study of cefuroxime axetil versus amoxicillin in children with early Lyme disease. Pediatrics 109 6 (2002) 1173-1177
69. Arnez M., Pleterski-Rigler D., Luznik-Bufon T., Ruzic-Sabljic E., and Strle F. Solitary erythema migrans in children: comparison of treatment with azithromycin and phenoxymethylpenicillin. Wien Klin Wochenschr. 114 13-14 (2002) 498-504
70. Cartter M.L., Hadler J.L., Gerber M.A., and Mofenson L. Lyme Disease and Pregnancy. Conn. Med. 53 6 (1989) 341-342
71. ACOG Committee opinion: committee on obstetrics: Maternal and fetal medecine. Lyme disease during pregnancy. Int. J. Gynecol. Obstet. 39 (1992) 59-60
72. Maraspin V., Cimperman J., Lotric-Furlan S., Pleterski-Rigler D., and Strle F. Erythema migrans in pregnancy. Wien Klin. Wochenschr. 111 22-23 (1999) 933-940
73. Maraspin V., Lotric-Furlan S., Cimperman J., Ruzic-Sabljic E., and Strle F. Erythema migrans in the immunocompromised host. Wien Klin. Wochenschr. 111 22-23 (1999) 923-932
74. Maraspin V., Cimperman J., Lotric-Furlan S., Logar M., Ruzic-Sabljic E., and Strle F. Erythema migrans in solid-organ transplant recipients. Clin. Infect. Dis. 42 12 (2006) 1751-1754
75. Wormser G.P., Nowakowski J., and Nadelman R.B. Duration of treatment for Lyme borreliosis: time for a critical reappraisal. Wien Klin Wochenschr. 114 13-14 (2002) 613-615
76. Wormser G.P., Ramanathan R., Nowakowski J., McKenna D., Holmgren D., Visintainer P., et al. Duration of antibiotic therapy for early Lyme disease. A randomized, double blind, placebo-controlled trial. Ann. Intern. Med. 138 9 (2003) 697-704
77. Wormser G.P., Dattwyler R.J., Dennis D.T., Shapiro E.D., Halperin J.J., et al. The Clinical Assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin. Infect. Dis. 43 (2006) 1089-1134
78. Smith M., Gettinby G., Granstrom M., Gray J.S., Guy E.C., Revie C., et al. The European Union Concerted Action World Wide Web site for Lyme borreliosis. Zentralbl. Bakteriol. 287 3 (1998) 266-269
79. Strle F. Principles of the diagnosis and antibiotic treatment of Lyme borreliosis. Wien Klin Wochenschr. 111 22-23 (1999) 911-915
80. Pavia C.S. Current and novel therapies for Lyme disease. Expert Opin. Investig. Drugs 12 6 (2003) 1003-1016
81. Cameron D., Gaito A., Harris N., Bach G., Bellovin S., Bock K., et al. Evidence-based guidelines for the management of Lyme disease. Expert Rev. Anti Infect. Ther. 2 1 Suppl (2004) S1-S13
82. Asch E.S., Bujak D.I., Weiss M., Peterson M.G., and Weinstein A. Lyme disease: an infectious and post-infectious syndrome. J. Rheumatol. 21 3 (1994) 454-461
83. Klempner M.S., Hu L.T., Evans J., Schmid C.H., Johnson G.M., Trevino R.P., et al. Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease. N. Engl. J. Med. 345 2 (2001) 85-92
84. Krupp L.B., Hyman L.G., Grimson R., Coyle P.K., Melville P., Ahnn S., et al. Study and treatment of post Lyme disease (STOP-LD): a randomized double masked clinical trial. Neurology 60 12 (2003) 1923-1930
85. Seltzer E.G., Gerber M.A., Cartter M.L., Freudigman K., and Shapiro E.D. Long-term outcomes of persons with Lyme disease. JAMA 283 5 (2000) 609-616
86. Shadick N.A., Phillips C.B., Sangha O., Logigian E.L., Kaplan R.F., Wright E.A., et al. Musculoskeletal and neurologic outcomes in patients with previously treated Lyme disease. Ann. Intern. Med. 131 12 (1999) 919-926
87. Reid M.C., Schoen R.T., Evans J., Rosenberg J.C., and Horwitz R.I. The consequences of overdiagnosis and overtreatment of Lyme disease: an observational study. Ann. Intern. Med. 128 5 (1998) 354-362
88. Nowakowski J., Nadelman R.B., Sell R., McKenna D., Cavaliere L.F., Holmgren D., et al. Long-term follow-up of patients with culture-confirmed Lyme disease. Am. J. Med. 115 2 (2003) 91-96
89. Kalish Robert K.R., and Taylor E. Evaluation of Study Patients with Lyme disease, 1-20-year follow-up. JID 183 (2001) 453-460
90. Smith R.P., Schoen R.T., Rahn D.W., Sikand V.K., Nowakowski J., Parenti D.L., et al. Clinical characteristics and treatment outcome of early Lyme disease in patients with microbiologically confirmed erythema migrans. Ann. Intern. Med. 136 6 (2002) 421-428
91. Lipsker D., Antoni-Bach N., Hansmann Y., and Jaulhac B. Long term prognosis of patients treated for erythema migrans in France. Br. J. Dermatol. 146 5 (2002) 872-876
92. Aberer E., Kehldorfer M., Binder B., and Schauperi H. The outcome of Lyme borreliosis in children. Wien Klin. Wochenschr. 111 22-23 (1999) 941-944
93. Gerber M.A., Shapiro E.D., Burke G.S., Parcells V.J., and Bell G.L. Lyme disease in children in southeastern Connecticut. Pediatric Lyme Disease Study Group. N. Engl. J. Med. 335 17 (1996) 1270-1274
94. Barskova V.G., Fedorov E.S., and Ananieva L.P. The course of Lyme disease in different age groups. Wien Klin. Wochenschr. 111 22-23 (1999) 978-980
95. Bartunek P., Mrazek V., Gorican K., Varejka P., Bina R., Rozmarova P., et al. Lyme borreliosis: waiting for Lyme carditis? A long-term prospective study. Prague Med. Rep. 106 1 (2005) 39-49
96. Morgen K., Martin R., Stone R.D., Grafman J., Kadom N., McFarland H.F., et al. FLAIR and magnetization transfer imaging of patients with post-treatment Lyme disease syndrome. Neurology 57 11 (2001) 1980-1985
97. Aguero-Rosenfeld M.E., Nowakowski J., Bittker S., Cooper D., Nadelman R.B., and Wormser G.P. Evolution of the serologic response to Borrelia burgdorferi in treated patients with culture-confirmed erythema migrans. J. Clin. Microbiol. 34 1 (1996) 1-9
98. Hofmann H. Lyme borreliosis: problems of serological diagnosis. Infection 24 6 (1996) 470-472
99. Hammers-Berggren S., Lebech A.M., Karlsson M., Svenungsson B., Hansen K., and Stiernstedt G. Serological follow-up after treatment of patients with erythema migrans and neuroborreliosis. J. Clin. Microbiol. 32 6 (1994) 1519-1525
100. Feder Jr. H.M., Gerber M.A., Luger S.W., and Ryan R.W. Persistence of serum antibodies to Borrelia burgdorferi in patients treated for Lyme disease. Clin. Infect. Dis. 15 5 (1992) 788-793
101. Dattwyler R.J., Volkman D.J., Luft B.J., Halperin J.J., Thomas J., and Golightly M.G. Seronegative Lyme disease. Dissociation of specific T- and B-lymphocyte responses to Borrelia burgdorferi. N. Engl. J. Med. 319 22 (1988) 1441-1446